CORMCO invests in public and private biotech companies that benefit from innovative product pipelines, demonstrated leadership, and solid financial performance.

CORMCO is an active biotech investor in the biopharma, genetics, life science, medical device, and therapeutics industries. CORMCO has made notable early investments in several top companies in the global biotech industry. Some of these investments include:

Biogen in 2005. Biogen specializes in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. It pioneers science and drives innovations for complex and devastating diseases. Biogen is among the 10 most valuable biotech companies in the world.

Natera in 2018. Natera is a clinical genetic testing company that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. It is considered a global leader in cell-free DNA testing and is among the 30 most valuable biotech companies in the world.

Karuna in 2018. Karuna is a biopharmaceutical company that develops and delivers transformative medicines for psychiatric and neurological conditions. Karuna was acquired by Bristol Myers Squibb in 2024. With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb.